1 / 0

December 2012

December 2012. BioGaia – a healthcare company in probiotics. Vision : BioGaia´s vision is to improve the health of people around the world by offering first class probiotic products.

terri
Download Presentation

December 2012

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. December 2012
  2. BioGaia – a healthcare company in probiotics Vision: BioGaia´s vision is to improve the health of people around the world by offering first class probiotic products. Business concept: BioGaia´s concept is to develop, market and sell well documented probiotic products worldwide in the form of innovative and appealing dietary supplements and food products. Probiotics:Live microorganisms which when administered in adequate amounts confer a documented health benefit.
  3. BioGaia Founded in 1990 Probiotics (strains of Lactobacillus reuteri) 74 employees (Stockholm 26, Lund 22, Eslöv 16, Raleigh 2, Hiroshima 6, Shanghai 2) Two segments: Finished consumer products/Component products More than 100 clinical studies Products in 60 markets through distributors Contract manufacturing TwoPac (50% owned) Holds over 200patents in 25 families
  4. Change of focus Dietary Supplements Infant formula Functional Foods / Dairies Animal Health 1990 1995 2000 2005 2010
  5. Business model – three networks
  6. Distribution partner network
  7. BioGaia Brand Branding for Health professionals Sold in over 40 countries 44% of sales of finished products (incl. co- branding 51%) Build value, less dependence on distributors and patents
  8. Competition Strategy Clinical trials of high quality Attractive and unique formulations and packaging solutions Strong partner support
  9. Scientific network
  10. Clinical trials supporting the use of BioGaia Probiotics with L. reuteri – including the strains L. reuteri Protectis, Prodentis and Gastrus Completed clinical trialsNov. 2012 108 trials in 8600 individuals whereof: 76 randomised, double-blind / blind, placebo-controlled studies in 6 800 subjects 32 open studies in 1 770 subjects 35 studies in 0-3y in 3 900 subjects Results are published in67scientific articles and 5 doctoral theses
  11. Product Indications Overview L. reuteri DSM 17938 (ATCC 55730) BioGaia ProTectis (82*) Gut Motility Diarrhoea Neonatal Intensive Care Regurgitation Necrotising Enterocolitis Prevention Gingivitis/plaque Infantile colic Acute Gastroenteritis Periodontitis Antibiotic AssociatedDiarrhoea (AAD) Constipation Feeding tolerance Functional abdominal Pain (FAP) BioGaia ProDentis (22*) L. reuteri DSM 17938 & L. reuteri ATCC PTA 5289 L. reuteri DSM 17938 & L. reuteri ATCC PTA 6485 BioGaia Gastrus (2*) Gum Integrity Stomach Health H. Pylori infection/inflammation H. pylori side effects * Number of completedclinical studies byNov 2012
  12. Health protection by L. reuteri Protectisin children Children (4-10 m) with increasedrisk for infection12 weekssupplementationin baby formula Weizman et al., Pediatr 115; 5-9 (2005)
  13. Health economics of L. reuteri Protectissupplementation Children (4-10 m) with increasedrisk for infection12 weekssupplementationin baby formula Weizman et al., Pediatr 115; 5-9 (2005)
  14. L. reuteri Protectisprevents antibiotic- associated diarrhoea Adults in hospital on antibiotics Supplemented with L. reuteri Protectisor placebo for 4 weeks Cimperman et al. ASPEN meeting February 2009
  15. L. reuteri Protectisreduces infantile colic ** *** Crying time (median; mins/day) *** *** ** *** p< 0.01 p< 0.001 Days of supplementation Savino et al. Pediatr Res 58: 411 (2005) Savino et al. Pediatr, in press (2006)
  16. Attractive and unique formulations and packaging solutions
  17. BioGaia product portfolio ProTectis Digestive Health ProDentis OralHealth Gastrus Stomach Health ProTectis Baby ProTectis D3 Baby ProTectis Junior ProTectis Baby/Junior ProTectis ProDentis ProDentis Gastrus Drops Lozenges Tablets Tablets ORS Tablets Drops Drops
  18. Strong partner support Clinical trials Marketing and PR support BioGaia Academy Web site Participation in conferences Speakers at symposiums Education of sales representatives
  19. Competitors Culture suppliers Chr Hansen Danisco InstitutRosellLallemand (France) Probiotic strains Valio (Finland) Probi (Sweden) Functional Foods Danone Yakult Pharma Merck (Germany) Novartis Sanofi Aventis Ferrosan (Pfizer) Other P&G Local competitors
  20. Launches and planned launches Drops: Launched in 51 countries (contracts but not launched in 27 countries) Tablets: Launched in 47 countries (contracts but not launched in 28 countries) ORS: Launched in 6 countries (contracts but not launched in 7 countries) Oral health products: Launched in 13 countries (contracts but not launched in 5 countries)
  21. Key events 2012 BioGaia extends collaboration with Nestlé Agreement with Gerber for sales of drops and ORS in United States Agreement with Nestlé for sales of drops in Mexico Agreement for oral health products in Czech Republic, the Benelux countries and South Africa Agreement for tablets and drops in Taiwan and Pakistan
  22. Key events 2012 (cont’d) Study in type 2 diabetes started Published studies: Study on reduction of diarrhoea in children New confirming study on colic Two studies on NEC in premature infants
  23. Nestlé Agreement Sale of licence for EUR 50.8 (EUR 40 million paid and accounted for in q1 2012) Further projects will be announced closer to launch (USAand Mexico) Revenue from Nestlé is estimated in 2012 (excluding the up-front payment) to 50% of sales during 2011, in 2013 close to 2011 level and from 2014 and forward more than 2011
  24. Sales development 2007-2011 (SEK Million) +36%
  25. EBIT and profit Profit Margin: 35% EbitMargin: 33% 103,2 Financial target: at least 30% EBIT margin EBIT margin = EBIT/Sales Profit margin = Profit before tax/Sales
  26. Income statement January - September, 2012vs2011
  27. Income statement Sept 2012 / Sept 2011 (rolling 12 months)
  28. Balance sheet September 30, 2012 (MSEK)
  29. Sales per segment (MSEK) (Licenserevenueexcluded)
  30. Sales per segment q1 2009- q3 2012, rolling 12 months, MSEK (License revenue excluded)
  31. Sales per geographical market(MSEK)
  32. The Board Jörgen Thorball Inger Holmström David Dangoor Chairman Paula Zeilon Jan Annwall Stefan Elving Thomas Flinck
  33. Major Shareholders 30 September 2012 Total number of shareholders 30 September 2012: 7,446 Foreign owners: 41% of capital (29% of votes)
  34. Present focus Continued focus on BRIC-countries Change of distributors in a number of countries A number of development projects with Nestlé Business model for Oral Health
More Related